20
Participants
Start Date
August 31, 2011
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
Arsenic Trioxide
Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
Emory University Winship Cancer Institute, Atlanta
Collaborators (1)
Cephalon
INDUSTRY
Teva Pharmaceuticals USA
INDUSTRY
National Cancer Institute (NCI)
NIH
Emory University
OTHER